long intergenic non-protein coding RNA 1885Genealiases: []
Q-omics provides the consensus-scored LINC01885 profile across patient tissues and cancer cell-line models. LINC01885 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01885 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, LINC01885 RNA expression shows 8,256 significant gene co-expression associations, with the highest sampling consensus in THCA. Together, these results highlight KIRC, and THCA as cancer lineages where LINC01885 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01885 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01885 survival associations across molecular data types. LINC01885 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01885 RNA expression–survival associations across cancer types. High LINC01885 expression shows unfavorable associations in COAD, LIHC, SKCM and KIRP, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01885 RNA expression.
This table summarizes LINC01885 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01885. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01885 shows lower tumor expression in THCA, HNSC and KICH and higher tumor expression in KIRC, LUSC and LIHC. The THCA box plot shows higher LINC01885 RNA expression in normal versus tumor tissue (log2 FC = −2.901, t-test p < 0.001).
This table shows molecular features associated with LINC01885 in patient tissues and cancer cell lines. In patient samples, LINC01885 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set.
